UnitedHealth enters its October 13, 2026, Q3 earnings release with an 82% market-implied probability of beating consensus EPS estimates near $4.00–$4.14, driven by sustained margin expansion and cost discipline. The company delivered large beats in Q1 and Q2 2026, with adjusted EPS of $7.23 and $6.38 respectively, prompting multiple upward revisions to full-year 2026 adjusted EPS guidance now at $19.50–$20.00. Key supports include a lower medical care ratio—down to 86.7% in Q2 from 89.4% a year earlier—alongside Medicare Advantage margin recovery above 3% and Optum segment strength. Traders view these operational improvements and prior outperformance as durable signals that current consensus remains conservative ahead of the print.